EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Anticoagulant therapy and altered tissue factor expression protect against experimental placental and cerebral malaria

Alicer K Andrew iD, Tara C Bracken, Nicole Nazario-Maldonado, Brittany N Russ, Kathyrn T Gonzalvo, Benjamin M Brainard, Nigel Mackman, Julie M Moore iD

PLOS Pathogens · 03.07.2025 · 21 (7) · e1013259

DOI: 10.1371/journal.ppat.1013259 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Pathogens, online erschienen am 03.07.2025. Verfasst von Alicer K Andrew und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, College of Veterinary Medicine, and Center for Tropical and Emerging Global Diseases, University of Georgia, Athen…. Hauptthemen laut MEDLINE: Malaria, Cerebral, Thromboplastin, Anticoagulants, Pregnancy Complications, Parasitic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NICHD NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Severe malaria remains a major public health concern in regions of moderate to high Plasmodium falciparum transmission. Women and young children are especially vulnerable to two clinical manifestations of severe P. falciparum malaria, known as placental malaria (PM) and cerebral malaria (CM). Both PM and CM have been characterized as procoagulant states; however, the role of coagulation in galvanizing poor health outcomes is incompletely understood. Moreover, the contribution of tissue factor (TF), the primary driver of the extrinsic pathway of coagulation, to the pathogenesis of PM and CM has not been fully explored. This work utilizes experimental murine models of PM (EPM) and CM (ECM) to explore the impact of anticoagulant treatment and tissue-specific or global reduction in TF expression on disease outcomes. In EPM, we show that treatment of wild-type mice with dalteparin, an anticoagulant class that is safe to use in humans during pregnancy, prevented malaria-induced pregnancy loss, significantly improved embryo viability, and decreased placental fibrin deposition at midgestation. Similarly, mice deficient for endothelial/hematopoietic TF, TF Tie2Δ , exhibited a superior ability to maintain their pregnancies at midgestation compared to TF-intact littermate controls, who unequivocally lost their pregnancies. Uterus weight and embryo viability were significantly improved in TF Tie2Δ dams despite experiencing similar parasite burdens as controls. In ECM, dalteparin treatment promoted preservation of the blood-brain barrier (BBB) and protected against the development of neurological signs. Likewise, mice genetically modified to have low TF expression (LTF) exhibited less perivascular leakage in the brain and significantly increased survival probability compared to their littermate controls (TFhet). Together, these data show that anticoagulant treatment can successfully protect against poor health outcomes in two murine models of severe malaria and identify a potentially universal role of TF in driving severe malaria pathogenesis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Malaria, CerebralThromboplastinAnticoagulantsPregnancy Complications, ParasiticMalaria, FalciparumAnimalsFemalePregnancyMicePlacentaDisease Models, AnimalMice, Inbred C57BLHumansMice, Knockout

Substanzen

ThromboplastinAnticoagulants

Autor:innen und Institutionen

  • Department of Infectious Diseases, College of Veterinary Medicine, and Center for Tropical and Emerging Global Diseases, University of Georgia, Athens, GeorgiaUnited States of America.
  • Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, Florida, United States of America.
  • Department of Small Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, Georgia, United States of America.
  • Department of Medicine, Division of Hematology, UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.

ORCID-Profile: Alicer K Andrew, Julie M Moore

Förderung

  • NIAID NIH HHS
  • NICHD NIH HHS
  • National Institutes of Health
  • National Science Foundation
  • College of Veterinary Medicine, University of Florida

Zitieren

APA

Andrew, A. K., Bracken, T. C., Nazario-Maldonado, N., Russ, B. N., Gonzalvo, K. T., Brainard, B. M., Mackman, N., & Moore, J. M. (2025). Anticoagulant therapy and altered tissue factor expression protect against experimental placental and cerebral malaria. PLOS Pathogens, 21(7), e1013259. https://doi.org/10.1371/journal.ppat.1013259

Vancouver

Andrew AK, Bracken TC, Nazario-Maldonado N, Russ BN, Gonzalvo KT, Brainard BM, et al. Anticoagulant therapy and altered tissue factor expression protect against experimental placental and cerebral malaria. PLOS Pathogens. 2025;21(7):e1013259. doi:10.1371/journal.ppat.1013259

BibTeX
@article{Andrew2025,
  author = {Andrew, Alicer K and Bracken, Tara C and Nazario-Maldonado, Nicole and Russ, Brittany N and Gonzalvo, Kathyrn T and Brainard, Benjamin M and Mackman, Nigel and Moore, Julie M},
  title = {Anticoagulant therapy and altered tissue factor expression protect against experimental placental and cerebral malaria},
  journal = {PLOS Pathogens},
  year = {2025},
  volume = {21},
  number = {7},
  pages = {e1013259},
  doi = {10.1371/journal.ppat.1013259}
}
Kostenlos starten →